Pharmaceutical Preparations
Standard Industrial Classification: SIC 2834
Industry Insider Sentiment Analysis
The Pharmaceutical Preparations sector (SIC 2834) acts as a critical barometer for broader economic health. Our real-time monitoring reveals total transactions. Monitoring "cluster buying" is one of the most reliable leading indicators for future sector performance. By analyzing aggregate data across this specific Standard Industrial Classification, investors can filter out individual company volatility and identify high-conviction trends. When multiple directors and officers within the same industry move capital simultaneously, it often signals an upcoming sector-wide revaluation or a fundamental shift in supply chain dynamics that has yet to be recognized by the broader public market.
| Filing Date | Trade Date | Ticker | Company | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-02-13 00:39 | 2026-02-10 | BBIO | BridgeBio Pharma, Inc. | Kumar Neil | Director, Officer | SELL | $71.86 | 80,000 | $5,748,664 | 4,478,447 |
| 2026-02-13 00:21 | 2026-02-10 | SDGR | Schrodinger, Inc. | Herman Jenny | Officer | SELL | $13.79 | 752 | $10,370 | 26,597 |
| 2026-02-13 00:23 | 2026-02-10 | SDGR | Schrodinger, Inc. | Tran Yvonne | Officer | SELL | $13.80 | 776 | $10,705 | 22,859 |
| 2026-02-13 00:22 | 2026-02-10 | SDGR | Schrodinger, Inc. | Lorton Kenneth Patrick | Officer | SELL | $13.73 | 925 | $12,704 | 52,651 |
| 2026-02-13 00:08 | 2026-02-10 | SGMT | Sagimet Biosciences Inc. | Happel David | Director, Officer | SELL | $5.36 | 12,101 | $64,865 | 677,621 |
| 2026-02-13 00:07 | 2026-02-10 | SGMT | Sagimet Biosciences Inc. | Chauche Thierry | Officer | SELL | $5.36 | 1,312 | $7,033 | 15,688 |
| 2026-02-13 00:06 | 2026-02-10 | SGMT | Sagimet Biosciences Inc. | Martins Eduardo Bruno | Officer | SELL | $5.36 | 3,640 | $19,511 | 103,296 |
| 2026-02-13 04:56 | 2026-02-10 | RYTM | RHYTHM PHARMACEUTICALS, INC. | Smith Hunter C | Officer | SELL | $100.21 | 7,071 | $708,576 | 118,466 |
| 2026-02-13 04:44 | 2026-02-11 | LYEL | Lyell Immunopharma, Inc. | Lee Gary K. | Officer | SELL | $23.39 | 1,671 | $39,085 | 16,938 |
| 2026-02-13 04:46 | 2026-02-11 | LYEL | Lyell Immunopharma, Inc. | Hill Stephen J. | Officer | SELL | $23.39 | 1,236 | $28,910 | 17,795 |
| 2026-02-13 04:47 | 2026-02-11 | LYEL | Lyell Immunopharma, Inc. | Seely Lynn | Director, Officer | SELL | $23.39 | 7,455 | $174,372 | 74,266 |
| 2026-02-13 01:45 | 2026-02-10 | MPLT | MapLight Therapeutics, Inc. | Malenka Robert C. | Director | SELL | $18.12 | 6,863 | $124,329 | 351,370 |
| 2026-02-13 01:45 | 2026-02-10 | MPLT | MapLight Therapeutics, Inc. | Garnett Timothy John | Director | BUY | $17.89 | 14,124 | $252,678 | 14,124 |
| 2026-02-13 01:08 | 2026-02-11 | VRTX | VERTEX PHARMACEUTICALS INC / MA | Tatsis Ourania | Officer | SELL | $460.43 | 466 | $214,560 | 51,436 |
| 2026-02-13 00:52 | 2026-02-11 | VRTX | VERTEX PHARMACEUTICALS INC / MA | Biller Jonathan | Officer | SELL | $460.43 | 1,925 | $886,328 | 20,819 |
| 2026-02-13 00:56 | 2026-02-11 | VRTX | VERTEX PHARMACEUTICALS INC / MA | Bunnage Mark E. | Officer | SELL | $460.43 | 2,021 | $930,529 | 12,914 |
| 2026-02-13 00:47 | 2026-02-11 | VRTX | VERTEX PHARMACEUTICALS INC / MA | Ambrose Kristen | Officer | SELL | $460.43 | 1,376 | $633,552 | 10,127 |
| 2026-02-13 00:50 | 2026-02-11 | VRTX | VERTEX PHARMACEUTICALS INC / MA | Atkinson Edward Morrow III | Officer | SELL | $460.43 | 1,751 | $806,213 | 22,046 |
| 2026-02-13 00:34 | 2026-02-10 | KNSA | Kiniksa Pharmaceuticals International, plc | Quart Barry D | Director | OPT+S | $45.00 | 2,800 | $126,000 | 12,546 |
| 2026-02-13 00:02 | 2026-02-12 | MRK | Merck & Co., Inc. | Guindo Chirfi | Officer | SELL | $121.46 | 10,000 | $1,214,562 | 60,615 |
| 2026-02-13 00:05 | 2026-02-10 | SGMT | Sagimet Biosciences Inc. | Rozek Elizabeth | Officer | SELL | $5.36 | 2,622 | $14,054 | 190,959 |
| 2026-02-12 05:00 | 2026-02-09 | WVE | Wave Life Sciences Ltd. | Vargeese Chandra | Officer | SELL | $13.45 | 3,228 | $43,417 | 408,246 |
| 2026-02-12 05:00 | 2026-02-10 | LYEL | Lyell Immunopharma, Inc. | Bulis Veronica Sanchez | Officer | SELL | $23.12 | 254 | $5,872 | 15,637 |
| 2026-02-12 05:01 | 2026-02-09 | WVE | Wave Life Sciences Ltd. | Francis Chris | Officer | SELL | $13.45 | 1,883 | $25,326 | 61,867 |
| 2026-02-12 05:02 | 2026-02-09 | WVE | Wave Life Sciences Ltd. | BOLNO PAUL | Director, Officer | SELL | $13.45 | 10,480 | $140,956 | 275,520 |
| 2026-02-12 05:03 | 2026-02-10 | LYEL | Lyell Immunopharma, Inc. | Seely Lynn | Director, Officer | SELL | $23.12 | 438 | $10,127 | 81,721 |
| 2026-02-12 05:03 | 2026-02-09 | WVE | Wave Life Sciences Ltd. | Moran Kyle | Officer | SELL | $13.45 | 3,588 | $48,259 | 134,385 |
| 2026-02-12 05:04 | 2026-02-10 | LYEL | Lyell Immunopharma, Inc. | Lee Gary K. | Officer | SELL | $23.12 | 147 | $3,399 | 18,609 |
| 2026-02-12 05:05 | 2026-02-10 | LYEL | Lyell Immunopharma, Inc. | Hill Stephen J. | Officer | SELL | $23.12 | 109 | $2,520 | 19,031 |
| 2026-02-12 02:58 | 2026-02-09 | MLYS | Mineralys Therapeutics, Inc. | Rodman David Malcom | Officer | OPT+S | $30.21 | 2,171 | $65,586 | 50,437 |
| 2026-02-12 02:27 | 2026-02-10 | PAHC | PHIBRO ANIMAL HEALTH CORP | BENDHEIM JACK | Director, Officer, 10% owner | SELL | $51.77 | 72,198 | $3,737,712 | 50,760 |
| 2026-02-12 01:53 | 2026-02-09 | ROIV | Roivant Sciences Ltd. | Sukhatme Mayukh | Director, Officer | OPT+S | $26.47 | 339,441 | $8,985,003 | 19,148,664 |
| 2026-02-12 02:00 | 2026-02-09 | SDGR | Schrodinger, Inc. | Abel Robert Lorne | Officer | SELL | $13.51 | 1,230 | $16,617 | 19,385 |
| 2026-02-12 00:38 | 2026-02-09 | KNSA | Kiniksa Pharmaceuticals International, plc | Ragosa Mark | Officer | OPT+S | $43.28 | 17,845 | $772,255 | 12,086 |
| 2026-02-12 00:42 | 2026-02-09 | INSM | INSMED Inc | Lewis William | Director, Officer | OPT+S | $147.79 | 13,396 | $1,979,764 | 301,185 |
| 2026-02-12 00:32 | 2026-02-09 | LFVN | Lifevantage Corp | Lewis Darwin | Director | BUY | $5.22 | 3,955 | $20,651 | 135,508 |
| 2026-02-12 00:02 | 2026-02-09 | REGN | REGENERON PHARMACEUTICALS, INC. | RYAN ARTHUR F | Director | SELL | $778.53 | 100 | $77,853 | 17,803 |
| 2026-02-12 00:03 | 2026-02-09 | REGN | REGENERON PHARMACEUTICALS, INC. | Pitofsky Jason | Officer | OPT+S | $778.52 | 2,036 | $1,585,058 | 4,272 |
| 2026-02-11 22:54 | 2026-02-03 | URGN | UroGen Pharma Ltd. | Smith Jason Drew | Officer | OPT+S | $19.69 | 7,479 | $147,262 | 55,588 |
| 2026-02-11 03:00 | 2026-02-06 | CING | Cingulate Inc. | Werth Peter J. | Director | BUY | $5.04 | 19,455 | $98,053 | 117,449 |
| 2026-02-11 03:00 | 2026-02-06 | CING | Cingulate Inc. | Callahan Jennifer L. | Officer | BUY | $5.04 | 4,864 | $24,515 | 5,059 |
| 2026-02-11 03:00 | 2026-02-06 | CING | Cingulate Inc. | Schaffer Shane J. | Director, Officer | BUY | $5.04 | 6,809 | $34,317 | 10,175 |
| 2026-02-11 03:00 | 2026-02-06 | CING | Cingulate Inc. | Brams Matthew | Officer | BUY | $5.04 | 1,946 | $9,808 | 4,656 |
| 2026-02-11 00:04 | 2026-02-10 | MRK | Merck & Co., Inc. | Li Dean Y | Officer | SELL | $117.52 | 10,235 | $1,202,844 | 92,035 |
| 2026-02-11 01:04 | 2026-02-06 | IONS | IONIS PHARMACEUTICALS INC | Monia Brett P | Director, Officer | SELL | $85.79 | 29,430 | $2,524,820 | 254,497 |
| 2026-02-11 00:30 | 2026-02-09 | UTHR | UNITED THERAPEUTICS Corp | BENKOWITZ MICHAEL | Officer | OPT+S | $474.65 | 22,500 | $10,679,686 | 0 |
| 2026-02-11 02:00 | 2026-02-09 | ACAD | Acadia Pharmaceuticals Inc. | Rhodes Jennifer J | Officer | OPT+S | $23.38 | 6,950 | $162,491 | 7,609 |
| 2026-02-11 05:09 | 2026-02-06 | ZNTL | Zentalis Pharmaceuticals, Inc. | EASTLAND JULIA MARIE | Director, Officer | SELL | $2.43 | 8,755 | $21,240 | 79,133 |
| 2026-02-11 05:10 | 2026-02-06 | ZNTL | Zentalis Pharmaceuticals, Inc. | Vultaggio Vincent | Officer | SELL | $2.43 | 40,224 | $97,555 | 146,506 |
| 2026-02-11 05:10 | 2026-02-06 | ZNTL | Zentalis Pharmaceuticals, Inc. | Bruns Ingmar | Officer | SELL | $2.43 | 3,297 | $7,999 | 33,332 |
Sector-Wide Insider Alpha
Analyzing insider movements across the Pharmaceutical Preparations sector provides a macro-view of executive conviction. When multiple leaders in different companies within the same SIC code (2834) simultaneously buy shares, it often indicates an industry-wide undervaluation or a positive shift in market cycles.
SEC Filings in Pharmaceutical Preparations
Every transaction in the Pharmaceutical Preparations industry is reported via Form 4 disclosures. By filtering these filings by industry, investors can detect institutional-scale sentiment shifts before they are reflected in broader market indices, following the capital flow of those with intimate industry knowledge.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.